1 Marengo, A., Rosso, C. & Bugianesi, E. Liver Cancer: Connections with Obesity, Fatty Liver, and Cirrhosis. Annu Rev Med 67, 103-117, doi:10.1146/annurev-med-090514-013832 (2016).
2 Aufhauser, D. D. et al. Incidence of Occult Intrahepatic Metastasis in Hepatocellular Carcinoma Treated With Transplantation Corresponds to Early Recurrence Rates After Partial Hepatectomy. Ann. Surg. 267, 922-928, doi:10.1097/sla.0000000000002135 (2018).
3 Su, Y. H., Kim, A. K. & Jain, S. Liquid biopsies for hepatocellular carcinoma. Transl Res 201, 84-97, doi:10.1016/j.trsl.2018.07.001 (2018).
4 Cheng, A. L., Shen, Y. C. & Zhu, A. X. Targeting Fibroblast Growth Factor Receptor Signaling in Hepatocellular Carcinoma. Oncology-Basel 81, 372-380, doi:10.1159/000335472 (2011).
5 Joliat, G. R., Hahnloser, D., Demartines, N. & Schafer, M. Future development of gastrointestinal cancer incidence and mortality rates in Switzerland: a tumour registry- and population-based projection up to 2030. Swiss Med Wkly 145, doi:ARTN w14188
10.4414/smw.2015.14188 (2015).
6 Zhang, X. F., Li, J., Shen, F. & Lau, W. Y. Significance of presence of microvascular invasion in specimens obtained after surgical treatment of hepatocellular carcinoma. J Gastroen Hepatol 33, 347-354, doi:10.1111/jgh.13843 (2018).
7 Lachenmayer, A., Alsinet, C., Chang, C. Y. & Llovet, J. M. Molecular approaches to treatment of hepatocellular carcinoma. Digest Liver Dis 42, S264-S272, doi:Doi 10.1016/S1590-8658(10)60515-4 (2010).
8 He, L. E. et al. Functions of N6-methyladenosine and its role in cancer. Mol Cancer 18, doi:ARTN 176
10.1186/s12943-019-1109-9 (2019).
9 Chen, B., Li, Y., Song, R. F., Xue, C. & Xu, F. Functions of RNA N6-methyladenosine modification in cancer progression. Molecular Biology Reports 46, 2567-2575, doi:10.1007/s11033-019-04655-4 (2019).
10 Yue, Y. N., Liu, J. Z. & He, C. RNA N-6-methyladenosine methylation in post-transcriptional gene expression regulation. Genes Dev. 29, 1343-1355, doi:10.1101/gad.262766.115 (2015).
11 Alarcon, C. R., Lee, H., Goodarzi, H., Halberg, N. & Tavazoie, S. F. N-6-methyladenosine marks primary microRNAs for processing. Nature 519, 482-+, doi:10.1038/nature14281 (2015).
12 Yang, J., Chen, J., Fei, X., Wang, X. & Wang, K. N6-methyladenine RNA modification and cancer. Oncology letters 20, 1504-1512, doi:10.3892/ol.2020.11739 (2020).
13 Zhao, X. et al. FTO-dependent demethylation of N6-methyladenosine regulates mRNA splicing and is required for adipogenesis. Cell Res 24, 1403-1419, doi:10.1038/cr.2014.151 (2014).
14 Ben-Haim, M. S., Moshitch-Moshkovitz, S. & Rechavi, G. FTO: linking m(6)A demethylation to adipogenesis. Cell Res 25, 3-4, doi:10.1038/cr.2014.162 (2015).
15 Mathiyalagan, P. et al. FTO-Dependent N-6-Methyladenosine Regulates Cardiac Function During Remodeling and Repair. Circulation 139, 518-532, doi:10.1161/Circulationaha.118.033794 (2019).
16 Wu, R. F. et al. FTO regulates adipogenesis by controlling cell cycle progression via m(6)A-YTHDF2 dependent mechanism. Bba-Mol Cell Biol L 1863, 1323-1330, doi:10.1016/j.bbalip.2018.08.008 (2018).
17 Wu, R. F. et al. Epigallocatechin gallate targets FTO and inhibits adipogenesis in an mRNA m(6)A-YTHDF2-dependent manner. Int J Obesity 42, 1378-1388, doi:10.1038/s41366-018-0082-5 (2018).
18 Li, Z. J. et al. FTO Plays an Oncogenic Role in Acute Myeloid Leukemia as a N-6-Methyladenosine RNA Demethylase. Cancer Cell 31, 127-141, doi:10.1016/j.ccell.2016.11.017 (2017).
19 Chen, J. L. & Du, B. Novel positioning from obesity to cancer: FTO, an m(6)A RNA demethylase, regulates tumour progression. J Cancer Res Clin 145, 19-29, doi:10.1007/s00432-018-2796-0 (2019).
20 Huang, Y. et al. Small-Molecule Targeting of Oncogenic FTO Demethylase in Acute Myeloid Leukemia. Cancer Cell 35, 677-+, doi:10.1016/j.ccell.2019.03.006 (2019).
21 Yan, F. et al. A dynamic N-6-methyladenosine methylome regulates intrinsic and acquired resistance to tyrosine kinase inhibitors. Cell Res 28, 1062-1076, doi:10.1038/s41422-018-0097-4 (2018).
22 Cui, Q. et al. m(6)A RNA Methylation Regulates the Self-Renewal and Tumorigenesis of Glioblastoma Stem Cells. Cell Reports 18, 2622-2634, doi:10.1016/j.celrep.2017.02.059 (2017).
23 Zhou, S. et al. FTO regulates the chemo-radiotherapy resistance of cervical squamous cell carcinoma (CSCC) by targeting -catenin through mRNA demethylation. Mol Carcinogen 57, 590-597, doi:10.1002/mc.22782 (2018).
24 Xu, D. et al. FTO expression is associated with the occurrence of gastric cancer and prognosis. Oncology Reports 38, 2285-2292, doi:10.3892/or.2017.5904 (2017).
25 Rong, Z. X. et al. Downregulation of Fat Mass and Obesity Associated (FTO) Promotes the Progression of Intrahepatic Cholangiocarcinoma. Front. Oncol. 9, doi:ARTN 369
10.3389/fonc.2019.00369 (2019).
26 Delahanty, R. J. et al. Association of Obesity-related Genetic Variants With Endometrial Cancer Risk: A Report From the Shanghai Endometrial Cancer Genetics Study. Am J Epidemiol 174, 1115-1126, doi:10.1093/aje/kwr233 (2011).
27 Shim, S. R. & Kim, S. J. Intervention meta-analysis: application and practice using R software. Epidemiology and health 41, e2019008, doi:10.4178/epih.e2019008 (2019).
28 Su, R. et al. R-2HG Exhibits Anti-tumor Activity by Targeting FTO/m(6)A/MYC/CEBPA Signaling. Cell 172, 90-+, doi:10.1016/j.cell.2017.11.031 (2018).
29 Tan, A. H., Dang, Y. W., Chen, G. & Mo, Z. N. Overexpression of the fat mass and obesity associated gene (FTO) in breast cancer and its clinical implications. Int J Clin Exp Patho 8, 13405-13410 (2015).
30 Li, Y. et al. Expression of Demethylase Genes, FTO and ALKBH1, Is Associated with Prognosis of Gastric Cancer. Dig. Dis. Sci. 64, 1503-1513, doi:10.1007/s10620-018-5452-2 (2019).
31 Deng, X. L., Su, R., Stanford, S. & Chen, J. J. Critical Enzymatic Functions of FTO in Obesity and Cancer. Front Endocrinol 9, doi:UNSP 396
10.3389/fendo.2018.00396 (2018).
32 Tang, H. D., Qiao, J. & Fu, Y. X. Immunotherapy and tumor microenvironment. Cancer Lett 370, 85-90, doi:10.1016/j.canlet.2015.10.009 (2016).
33 Zhang, Z. B. et al. Estrogen induces endometrial cancer cell proliferation and invasion by regulating the fat mass and obesity-associated gene via PI3K/AKT and MAPK signaling pathways. Cancer Lett 319, 89-97, doi:10.1016/j.canlet.2011.12.033 (2012).
34 Jiao, Y., Li, Y. Q., Lu, Z. Y. & Liu, Y. H. High Trophinin-Associated Protein Expression Is an Independent Predictor of Poor Survival in Liver Cancer. Dig. Dis. Sci. 64, 137-143, doi:10.1007/s10620-018-5315-x (2019).
35 Zucman-Rossi, J., Villanueva, A., Nault, J. C. & Llovet, J. M. Genetic Landscape and Biomarkers of Hepatocellular Carcinoma. Gastroenterology 149, 1226-+, doi:10.1053/j.gastro.2015.05.061 (2015).
36 Denkert, C. et al. Strategies for developing Ki67 as a useful biomarker in breast cancer. Breast 24, S67-S72, doi:10.1016/j.breast.2015.07.017 (2015).
37 Li, S. T. et al. Loss of PTEN expression in breast cancer: association with clinicopathological characteristics and prognosis. Oncotarget 8, 32043-32054, doi:10.18632/oncotarget.16761 (2017).
38 Hoshida, Y. et al. Gene Expression in Fixed Tissues and Outcome in Hepatocellular Carcinoma. New Engl J Med 359, 1995-2004, doi:10.1056/NEJMoa0804525 (2008).
39 King, L. Y. et al. A genomic and clinical prognostic index for hepatitis C-related early-stage cirrhosis that predicts clinical deterioration. Gut 64, 1296-1302, doi:10.1136/gutjnl-2014-307862 (2015).